Value Analysis - ATRS Short Then Position LongATRS is showing strong growth on the books with ever-increasing revenue per year, positive EPS, and ever-improving equity and asset management.
The 10 years discounted cash flows model indicates that the company's stock is currently undervalued at between $4.39 and $5.64 (26.9% - 63%)
Technical analysis indicates that bulls have oversaturated the market and we may see a retracement of 6-8% before the share price continues to climb.
ATRS
ATRS - 10.09% Potential Profit - Bullish PennantApproach this with extra-care, allocate less than usual, and take profit fast.
This is a penny stock and a high-risk / high-reward scenario.
Clear 6-month uptrend Support with a Bullish Pennant formed within.
Target price set at a new potential resistance line.
I suggest entering a Buy Stop order. If the stop price is not triggered, I wouldn't try to chase a dead-cat bounce. Keep Stop Loss tight and adjust accordingly to protect profits.
- 6-month uptrend
- RSI + Stoch above 50
- MACD above Signal.
Suggested Entry $3.10
Suggested Stop Loss $2.96
Target price $3.42
Note that I tend to adjust stop losses in order to secure profits early and preserve capital. This means that the target price is going to be achieved as long as there are no strong pullbacks that trigger my new adjusted stop loss.
$ATRS Play The Breakout Above $3.96It's been 2 years since $ATRS was last above $4 a share.
Might be some fireworks next week.
Antares Pharma, Inc. (ATRS) today announced that Robert F. Apple, President and Chief Executive Officer, will present at the Ladenburg Thalmann 2019 Healthcare Conference on Tuesday, September 24, 2019 at 12:00 p.m. Eastern Time.
About Antares Pharma
Antares Pharma, Inc. is a combination drug device company focused primarily on the development and commercialization of self-administered parenteral pharmaceutical products using advanced drug delivery auto injector technology. The Company has a portfolio of proprietary and partnered commercial products with several product candidates in various stages of development, as well as significant strategic alliances with industry leading pharmaceutical companies including Teva Pharmaceutical Industries, Ltd. (Teva), AMAG Pharmaceuticals, Inc. and Pfizer Inc. (Pfizer). Antares Pharma’s proprietary products include XYOSTED® (testosterone enanthate) injection, OTREXUP® (methotrexate) injection for subcutaneous use and Sumatriptan Injection USP, which is distributed by Teva.
As always, trade with caution and use protective stops.
Good luck to all!
ATRS ideasSitting at a crucial point now. Current range in between 2.4 - 2.5.
Reversal might happen however signal appears to be weakish, would like a strong confirmation tomorrow
If ATRS breaks below the range, it's going to have a hard time coming back up
ATRS HAS BROKEN THE UPTREND: ONE MORE WAVE DOWN?ATRS has broken the uptrend with a strong impulse. I'm looking for a potential bounce before one more wave down. Bearish divergence on 4h chart.
$ATRS recent insider purchase and high short interest$ATRS not my typical play but recent insiders and fairly high short interest
Settlement Date Short Interest Avg Daily Share Volume Days To Cover
3/15/2016 10,444,826 866,786 12.050063
